September 29, 2016 / 5:36 AM / a year ago

BRIEF-Ablynx to present additional data on caplacizumab

Sept 29 (Reuters) - Ablynx NV :

* Announces that it will today present additional data from post-hoc analyses of the Phase II TITAN study of its wholly-owned Nanobody, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (aTTP)

* Says caplacizumab may have the potential to reduce morbidity and mortality associated with acquired aTTP Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below